SCHEMBL2371333

SCHEMBL2371333

CCCSc1nc(-c2ccccc2)cn2c(-c3ccc(C(=O)NC4CC4)cc3)cnc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
TTK P33981 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2371197 0.95 TTK (1.00) TTK
SCHEMBL2371077 0.95 TTK (1.00) TTK
SCHEMBL2372670 0.93 TTK (1.00) TTK
SCHEMBL2372438 0.91 TTK (0.84) TTK
SCHEMBL2371642 0.91 TTK (1.00) TTK
SCHEMBL2371579 0.91 TTK (1.00) TTK
SCHEMBL12300350 0.91 TTK (0.83) TTK
SCHEMBL14629835 0.91 TTK (0.83) TTK
SCHEMBL2371224 0.90 TTK (1.00) TTK
SCHEMBL2371200 0.89 TTK (1.00) TTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9468642-B2 Imidazopyrazines BAYER INTELLECTUAL PROPERTY GMBH (DE) 2016-10-18 US claimed
EP-2547680-B1 IMIDAZOPYRAZINES BAYER IP GMBH (DE) 2015-08-05 EP claimed
US-20130195848-A1 IMIDAZOPYRAZINES BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-08-01 US claimed
EP-2547680-A1 IMIDAZOPYRAZINES Bayer Intellectual Property GmbH (DE) 2013-01-23 EP claimed
WO-2011113862-A1 IMIDAZOPYRAZINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2011-09-22 WO claimed
US-9468642-B2 Imidazopyrazines BAYER INTELLECTUAL PROPERTY GMBH (DE) 2016-10-18 US disclosed
US-9468642-B2 Imidazopyrazines BAYER INTELLECTUAL PROPERTY GMBH (DE) 2016-10-18 US disclosed
US-9468642-B2 Imidazopyrazines BAYER INTELLECTUAL PROPERTY GMBH (DE) 2016-10-18 US disclosed
EP-2547680-B1 IMIDAZOPYRAZINES BAYER IP GMBH (DE) 2015-08-05 EP disclosed
US-20130195848-A1 IMIDAZOPYRAZINES BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-08-01 US disclosed
US-20130195848-A1 IMIDAZOPYRAZINES BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-08-01 US disclosed
US-20130195848-A1 IMIDAZOPYRAZINES BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-08-01 US disclosed
EP-2547680-A1 IMIDAZOPYRAZINES Bayer Intellectual Property GmbH (DE) 2013-01-23 EP disclosed
WO-2011113862-A1 IMIDAZOPYRAZINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2011-09-22 WO disclosed
WO-2011113862-A1 IMIDAZOPYRAZINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2011-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130195848-A1 IMIDAZOPYRAZINES F12, C1R, XDH TTK 4007/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.